The serum expression of selected miRNAs in pulmonary sarcoidosis with/without Löfgren's syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33160597" target="_blank" >RIV/61989592:15110/16:33160597 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.hindawi.com/journals/mi/2016/1246129/" target="_blank" >https://www.hindawi.com/journals/mi/2016/1246129/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2016/1246129" target="_blank" >10.1155/2016/1246129</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The serum expression of selected miRNAs in pulmonary sarcoidosis with/without Löfgren's syndrome

Popis výsledku v původním jazyce

Abstract Purpose. Pulmonary sarcoidosis is associated with dysregulated expression of intracellular miRNAs. There is however only little information on extracellular miRNAs and their association with the disease course in sarcoidosis. We therefore assessed serum miRNAs in sarcoidosis classified according to the presence of Löfgren's syndrome (LS) as a hallmark of good prognosis in contrast to more advanced disease course. Methods. RT-PCR was used to assess 35 miRNAs in 13 healthy controls and 24 sarcoidosis patients (12 with X-ray (CXR) stage LESS-THAN OR EQUAL TO 1 and LS and 12 with insidious onset and CXR stage GREATER-THAN OR EQUAL TO 3). Results. Compared to controls, we consistently observed dysregulated expressions of miR-146, miR-16, miR-425-5p, and miR-93-5p in both sarcoidosis groups irrespective of disease course. Specifically, patients without LS had dysregulated expressions of miR-150-5p, miR-1, and miR-212 compared to controls. Patients with LS had dysregulated expressions of miR-21-5p and miR-340-5p compared to controls. Bioinformatics predicted consistently "Pathways in cancer" to be modulated by both altered profiles in patients with/without LS. Three miRNAs (miR-21-5p, miR-340-5p, and miR-212-3p) differed between our patients with LS and those without LS; their cumulative effect may modulate "TGF-β signalling pathway." Conclusions. Further study should focus on possible applications of serum miRNAs for diagnostics follow-up and for prognosis.

Název v anglickém jazyce

The serum expression of selected miRNAs in pulmonary sarcoidosis with/without Löfgren's syndrome

Popis výsledku anglicky

Abstract Purpose. Pulmonary sarcoidosis is associated with dysregulated expression of intracellular miRNAs. There is however only little information on extracellular miRNAs and their association with the disease course in sarcoidosis. We therefore assessed serum miRNAs in sarcoidosis classified according to the presence of Löfgren's syndrome (LS) as a hallmark of good prognosis in contrast to more advanced disease course. Methods. RT-PCR was used to assess 35 miRNAs in 13 healthy controls and 24 sarcoidosis patients (12 with X-ray (CXR) stage LESS-THAN OR EQUAL TO 1 and LS and 12 with insidious onset and CXR stage GREATER-THAN OR EQUAL TO 3). Results. Compared to controls, we consistently observed dysregulated expressions of miR-146, miR-16, miR-425-5p, and miR-93-5p in both sarcoidosis groups irrespective of disease course. Specifically, patients without LS had dysregulated expressions of miR-150-5p, miR-1, and miR-212 compared to controls. Patients with LS had dysregulated expressions of miR-21-5p and miR-340-5p compared to controls. Bioinformatics predicted consistently "Pathways in cancer" to be modulated by both altered profiles in patients with/without LS. Three miRNAs (miR-21-5p, miR-340-5p, and miR-212-3p) differed between our patients with LS and those without LS; their cumulative effect may modulate "TGF-β signalling pathway." Conclusions. Further study should focus on possible applications of serum miRNAs for diagnostics follow-up and for prognosis.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Mediators of Inflammation

ISSN

0962-9351

e-ISSN

—

Svazek periodika

2016

Číslo periodika v rámci svazku

1246129

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

"1246129-1"-"1246129-12"

Kód UT WoS článku

000390462000001

EID výsledku v databázi Scopus

2-s2.0-85008946375